Pembrolizumab for Melanoma

Phase-Based Progress Estimates
MelanomaPembrolizumab - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing how well radiation therapy, plasma exchange, and either pembrolizumab or nivolumab work in treating patients with melanoma.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Up to 2 years

Year 2
Overall survival (OS)
Year 2
Progression-free survival (PFS)
Up to 2 years
Effects of plasma exchange on immune cell function
Feasibility of treatment approach
Incidence of adverse events (AEs)
Kinetics of extracellular vesicles after plasma exchange in patients with melanoma
Kinetics of soluble (s)PD-L1 removal and regeneration by plasma exchange in patients with melanoma
Overall response rate

Trial Safety

Trial Design

1 Treatment Group

Treatment (radiation therapy, plasma exchange, immunotherapy)
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase < 1

Treatment (radiation therapy, plasma exchange, immunotherapy)Experimental Group · 4 Interventions: Pembrolizumab, Therapeutic Exchange Plasma, Nivolumab, Radiation Therapy · Intervention Types: Biological, Biological, Biological, Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
Radiation Therapy
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,072 Previous Clinical Trials
41,128,898 Total Patients Enrolled
543 Trials studying Melanoma
157,021 Patients Enrolled for Melanoma
Mayo ClinicLead Sponsor
2,918 Previous Clinical Trials
3,506,960 Total Patients Enrolled
36 Trials studying Melanoma
2,034 Patients Enrolled for Melanoma
Jacob J OrmePrincipal InvestigatorMayo Clinic in Rochester
1 Previous Clinical Trials
15 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to return to the study institution for follow-up.
You are of childbearing potential.
You have a high level of sPD-L1 by ELISA.
The study apheresis technician determines that vascular access is feasible.
You provide written informed consent.
You are willing to provide blood samples for correlative research purposes.